News Center
The 2017 Pujiang Healthcare Industry & Finance Integration and Innovation Summit Releases the Shanghai Consensus on China Healthcare Industry & Finance Integration and Innovation

The 2017 Pujiang Healthcare Industry & Finance Integration and Innovation Summit was held in Shanghai International Convention Center on May 18. According to the Shanghai Consensus on China Healthcare Industry & Finance Integration and Innovation released at the Summit, industry and finance integration will help boost the innovation and transformation of China’s pharmaceutical industry.

The Summit was sponsored by Chinese Pharmaceutical Enterprises Association and China Pharmaceutical Industry Association and undertaken by the Healthcare Executive Journal, with Shanghai Pharma as the initiator and strategic cooperation partner. The SIIC President and Shanghai Pharma Chairman Mr. Zhou Jun attended the Summit and delivered an opening speech. Mr. Cho Man, Executive Director and President of Shanghai Pharma, and Mr. Liu Yanjun, Vice President of Shanghai Pharma and President of Central Research Institute, attended the Roundtable Dialogue on Integration of R&D, Industry and Finance under the New Situation.

Mr. Zhou Jun said that China’s pharmaceutical industry is noted to have a world-class market place without any world-class companies and products and that makes an opportunity. Over time, among the domestic pharmaceutical companies, there must be a number of World Top 500 enterprises emerging with sales revenue over 100 billion US dollars and market value exceeding tens of billions of US dollars. One of the expectable approaches is to take advantage of the power of capital and realize the integration of industry and finance. Mr. Zhou Jun said that over the past two decades, SIIC has built three main pillar business - pharmaceutical, real estate and infrastructure & environmental protection - through 35-40 large mergers and acquisitions.

During the Roundtable Dialogue on Integration of R&D, Industry and Finance under the New Situations”, Mr. Cho Man pointed out that innovation is the only way for China’s pharmaceutical industry to turn from a big player into a powerful player. In recent years, Shanghai Pharma has been attaching great importance to R&D and innovation with more investment made than ever, which has accounted for 5.4% of its industrial revenues. In the future, the investment will be further stepped up. Meanwhile, Shanghai Pharma has made constant innovation in terms of R&D system and model and carried out R&D cooperation with Chinese and foreign companies scientific research institutes. However, the road of innovation is always filled with hardships, which demands seamless linkage and full cooperation throughout all links along the whole innovation chain including basic research, clinical and market.

Mr. Liu Yanjun announced the Shanghai Consensus on China Healthcare Industry & Finance Integration and Innovation. It is pointed out in the Shanghai Consensus that China’s pharmaceutical industry will enter a brand-new era featuring innovation and compliance, in which precision medicine model will lead the industry development, innovation will be integrated with capital investment, and competition will come along with sharing along the industrial eco-chain. For each and every participant in this industry, the future is filled with challenges and opportunities. We must work together to embrace industry change, face challenges and seek opportunities. The Government should offer guidance on the establishment of a management system of precision medical data and encourage enterprises to be engaged in precision medicine. Consistency evaluation represents a reshuffling opportunity for China’s pharmaceutical industry. The industry and finance integration will boost the innovation and transformation of China’s pharmaceutical industry.

As a chairman unit of the Innovation Work Committee of China Pharmaceutical Industry Association, Shanghai Pharma initiated the Summit with an intention to promote the professional capability of investment and coordinate industry development. With an aim to boost innovation and globalization of China’s healthcare industry, efforts shall be made to build an eco-circle of medical R&D, production and finance by incorporating the scientists, entrepreneurs and investors engaged in the healthcare industry chain, so as to help Chinese pharmaceutical companies make the list of top three pharmaceutical companies in the world and beckon the emergence of world-class healthcare companies in China.

The Summit focused on translational medicine, market prospects and investment cooperation opportunities, shared the new development trends, new technologies and new breakthroughs in the industry, and provided a multi-layer, diversified and efficient communication platform for many start-ups and investors. The Summit gathered two academicians and over 20 key entrepreneurs, investors and scientists. 13 projects from West China Hospital, Sichuan University, Shenyang Pharmaceutical University, Tongji University, China Pharmaceutical University and University of Pittsburgh presented their road shows at the Summit with an expectation to seek potential cooperation in the future.

 

The subject of concern
Produced By 大汉网络 大汉版通发布系统